MX2023004333A - Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. - Google Patents

Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Info

Publication number
MX2023004333A
MX2023004333A MX2023004333A MX2023004333A MX2023004333A MX 2023004333 A MX2023004333 A MX 2023004333A MX 2023004333 A MX2023004333 A MX 2023004333A MX 2023004333 A MX2023004333 A MX 2023004333A MX 2023004333 A MX2023004333 A MX 2023004333A
Authority
MX
Mexico
Prior art keywords
antibody fragments
monovalent anti
antibodies
properdin antibodies
properdin
Prior art date
Application number
MX2023004333A
Other languages
English (en)
Inventor
Paul P Tamburini
Douglas L Sheridan
Taneisha Ann- Tanara Mack
Walter C Voegtli
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of MX2023004333A publication Critical patent/MX2023004333A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se describen en la presente anticuerpos monovalentes aislados o fragmentos de anticuerpo del mismo que se unen a properdina humana. Esos anticuerpos son usados en un método de tratamiento para enfermedades mediadas por desregulación de la vía alternativa del complemento.
MX2023004333A 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo. MX2023004333A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762452187P 2017-01-30 2017-01-30

Publications (1)

Publication Number Publication Date
MX2023004333A true MX2023004333A (es) 2023-05-04

Family

ID=62978808

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2019008827A MX2019008827A (es) 2017-01-30 2018-01-30 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2023007840A MX2023007840A (es) 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2023004333A MX2023004333A (es) 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2019008827A MX2019008827A (es) 2017-01-30 2018-01-30 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
MX2023007840A MX2023007840A (es) 2017-01-30 2019-07-25 Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.

Country Status (12)

Country Link
US (2) US11198725B2 (es)
EP (1) EP3573661A4 (es)
JP (2) JP7101684B2 (es)
KR (2) KR20230173731A (es)
CN (1) CN110831626B (es)
AU (1) AU2018212012A1 (es)
BR (1) BR112019014652A2 (es)
CA (1) CA3049806A1 (es)
CO (1) CO2019007686A2 (es)
IL (2) IL309890A (es)
MX (3) MX2019008827A (es)
WO (1) WO2018140956A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117327187A (zh) 2017-07-11 2024-01-02 亚力兄制药公司 结合补体成分c5或血清白蛋白的多肽及其融合蛋白
US20220053741A1 (en) * 2018-09-13 2022-02-24 Regeneron Pharmaceuticals, Inc. Complement Factor H Gene Knockout Rat as a Model of C3 Glomerulopathy
US20230054202A1 (en) * 2020-01-08 2023-02-23 Zydus Lifesciences Limited Anti-properdin antibodies and preparation thereof
WO2022089576A1 (zh) * 2020-10-30 2022-05-05 广州市妇女儿童医疗中心 用于抑制mhc-i和/或ii信号通路的试剂在治疗胆道闭锁中的应用
WO2023023227A1 (en) 2021-08-20 2023-02-23 Alexion Pharmaceuticals, Inc. Methods for treating sickle cell disease or beta thalassemia using complement alternative pathway inhibitors
WO2024049951A1 (en) * 2022-08-31 2024-03-07 Alexion Pharmaceuticals, Inc. Dosage and administration of fusion polypeptides for treatment of sickle cell disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521540A (en) 2000-04-11 2004-09-24 Genentech Inc Multivalent antibodies and uses therefor
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same
JP5735194B2 (ja) 2005-01-25 2015-06-17 セル セラピューティクス インコーポレーテッド 改善された生体内半減期を有する生物学的に活性なタンパク質
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR20180002911A (ko) * 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
ES2538114T3 (es) * 2008-03-03 2015-06-17 Novelmed Therapeutics, Inc. Anticuerpos anti-properdina
US20110002931A1 (en) 2009-06-23 2011-01-06 Alexion Pharmaceuticals, Inc. Bispecific antibodies that bind to complement proteins
AU2011224224B2 (en) * 2010-03-10 2015-07-09 Novelmed Therapeutics, Inc. Humanized and chimeric anti-properdin antibodies
US9701742B2 (en) * 2011-07-01 2017-07-11 The Trustees Of The University Of Pennsylvania Anti-properdin antibodies and uses thereof
WO2013009545A1 (en) * 2011-07-08 2013-01-17 Amylin Pharmaceuticals, Inc. Engineered polypeptides having enhanced duration of action with reduced immunogenicity
CA2859493A1 (en) 2011-12-21 2013-06-27 Novartis Ag Compositions and methods for antibodies targeting factor p
EP2797629A4 (en) * 2011-12-28 2015-09-30 Novelmed Therapeutics Inc AGLYCOSYLATED HUMAN ANTIBODY AND FUSION PROTEIN AND USES THEREOF
US9926366B2 (en) * 2012-10-04 2018-03-27 Novelmed Therapeutics, Inc. Methods of treating a hemolytic disorder comprising administering anti-properdin antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
CN110003335B (zh) * 2019-04-12 2023-07-04 深圳普瑞金生物药业股份有限公司 Cd47单域抗体、核酸及试剂盒

Also Published As

Publication number Publication date
JP2020507561A (ja) 2020-03-12
CO2019007686A2 (es) 2019-07-31
MX2023007840A (es) 2023-07-07
RU2019124873A3 (es) 2021-03-01
US20190352381A1 (en) 2019-11-21
CN110831626A (zh) 2020-02-21
AU2018212012A1 (en) 2019-07-25
KR20230173731A (ko) 2023-12-27
KR102613874B1 (ko) 2023-12-15
KR20190111946A (ko) 2019-10-02
IL267898B1 (en) 2024-02-01
EP3573661A4 (en) 2020-08-12
WO2018140956A1 (en) 2018-08-02
BR112019014652A2 (pt) 2020-08-18
MX2019008827A (es) 2019-09-26
IL267898A (en) 2019-09-26
US20220162292A1 (en) 2022-05-26
EP3573661A1 (en) 2019-12-04
JP2022153405A (ja) 2022-10-12
IL309890A (en) 2024-03-01
CN110831626B (zh) 2024-04-19
US11198725B2 (en) 2021-12-14
CA3049806A1 (en) 2018-08-02
RU2019124873A (ru) 2021-03-01
JP7101684B2 (ja) 2022-07-15

Similar Documents

Publication Publication Date Title
MX2023007840A (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo.
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
EA201792221A1 (ru) Антитела против сортилина и способы их применения
CR20190485A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
NZ738008A (en) Tigit-binding agents and uses thereof
GEP20227343B (en) Anti-lag3 antibodies and antigen-binding fragments
MX2022005253A (es) Anticuerpos neutralizantes de poliomavirus.
MX2022008523A (es) Compuestos que interactuan con glicanos y metodos de uso.
PH12017501522B1 (en) Antibodies to tau and uses thereof
MX2023000738A (es) Proteinas de union a antigeno que activan el receptor de leptina.
NZ626242A (en) Anti-asic1 antibodies and uses thereof
MX2020008122A (es) Anticuerpos anti-pd-1.
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
PH12017502020A1 (en) Antibodies targeting bone morphogenetic protein 9 (bmp9) and methods therefor
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12019500342A1 (en) Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6
JOP20190101A1 (ar) أنظمة علاج
MA40536A (fr) Anticorps anti-alpha v bêta 5 humanisés et leurs utilisations
MX2022003523A (es) Proteinas de union a antigenos.
MX2017001983A (es) Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos.